Joey Azofeifa

So when I hear demagogues denounce "Big Pharma," I append my own branding: "Big Pharma. The people who rescue children from leukemia." END

@cellaritybio @MITdeptofBE @uwgenome @Novartis Thank you, @cellaritybio, for featuring our NRF2 program as part of your third annual symposium! Watch @JoeyAzofeifa 's presentation: “Massively high throughput transcriptomics discovers a molecular glue degrading NRF2 in lung cancer” at 12:45 ET. lnkd.in/ddxuVCt5

@waitbutwhy m.youtube.com/watch?v=ICv6GL…

Incredible display of zealot's corner

We’re also very excited to present our NRF2 degrader at @AACR! This amazing small molecule leads to regression of aggressive lung adenocarcinoma tumors in vivo and was discovered using our AI + transcriptomics platform. Stop by on April 8th from 1:30-5:00, Section 52, Board 15.

Strong Arpeggio representation at @SLAS_Org with Tim Read and Casey Pham both presenting today in collaboration with @BCILifeSciences and @Biosero 👏 Be sure to connect with our team if you're there!

@RecursionChris joey@arpeggiobio.com, in case that's helpful

@RecursionChris Would love to join the event if there is space! Have a great conference everyone!

Look forward to connecting with everyone at JPM! And if you haven’t gotten an invite to the awesome event we are co-hosting with NVIDIA, shoot me a DM and I’ll get one sent over!

@davisidarta @humancellatlas Doesn't this make sense given that gene expression and the information content of genes is non-uniformally distributed? The top 500 most variable / highest-expressed are also going to be the most compressable, so PCA should do this? Lmk if I am missthinking this :)

Many professional biotech investors and operators think that rare disease parents are just a bunch of moms and dads who could never become biotech CEOs. It’s true that most parents aren’t founders. But some are! And when lightning strikes them, they go to work finding cures.

We are proud to be selected by the @endpts editorial team as one of the most promising and ambitious #biotech startups! We’re grateful for the recognition of what we’ve built so far and where we are headed next: the clinic in 2024! endpts.com/the-endpoints-…

I am increasingly -tive biotech. (Consistent for past 3 years) Investors are creating their own problems. They do not want to take risks on novel science. Instead supporting IPOs of me-too drugs and targets. Then they are left with a sea of competition with marginal benefit.

Human trampling affects alpine plants differently, which has important conservation implications 🌱🦶🏔️Delighted to share my first publication from my @snsf_ch postdoctoral fellowship!doi.org/10.3390/plants…

How inspiring that we've made @Norrsken's Impact100, an annual list of the world's 100 most promising impact #startups - this list exists to give you energy, hope, and positive inspiration! #100waystofixthefuture #NASDAQ

@RecursionChris Any advise on hiring senior executives. Especially those with significant pharma discovery/development experience. Green flags and red flags to look out for as to whether they would integrate well with a TechBio platform company culture! Thank you very much!!

Hey #TechBio founders! I've been fielding lots of calls from you lately to think through some challenging situations - or just walking through various perspectives for you if it is your first-time through a certain thing as you build. I love spending that time with you, but it doesn't scale well and I can't always hop on a call or text with all of you. So I'm thinking about trying to write out some thoughts on some of these questions to make this work a little more available to folks. Anything challenges/worries/ideas you'd be interested in hearing about WRT building in techbio?

Because the average biotech CEO is a 54-year old guy named Mike who isn’t actually a nerd

We’re incredibly excited to publish the inaugural edition of the Decoding Bio Snapshot. Several months in the making, it profiles 40 companies operating at the intersection of computation and biology, ranging from pre-seed to publicly traded. snapshot.decodingbio.com

Awesome job to Dave Simpson for repping Arpeggio yesterday at the @CUBoulder Core Facilities Open House and Local Industry Fair!

Our CEO, @JoeyAzofeifa, will be talking at the BIO International Convention about how we're developing therapies for diseases driven by transcription factors! Please check out his talk on Wednesday June 7th at 4:15p ET in Room 104B! #StandUpForScience #BIO2023

@A_Mazzocchi @viswacolluru @Ali110Afshar @kpfortney @kamens @MikeDubrovsky @PatrickSkelly24 @hereisramji @allmeasures So excited and happy for you Andrea!!!!

@viswacolluru @JoeyAzofeifa @Ali110Afshar @kpfortney @kamens @MikeDubrovsky @PatrickSkelly24 @hereisramji @allmeasures, to name a few, have been friends and mentors on the rollercoaster ride. Thank you.

After announcing the acquisition earlier this week, I've been reminded of the incredible founder community I have had the opportunity to be part of If you start a company, find peers to build with, it will be one of the best things you do.

It’s important – personally as well as professionally – not to put people on a pedestal. When we assume person X or Y has had so much success that they couldn’t possibly want to talk to *us*, we subtly rob them of their humanity. Everyone is more than the net sum of their...1/9